Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Rifabutin And Lersivirine (UK-453,061) In Healthy Subjects.

Trial Profile

Open-Label, Randomized, 3-Way Crossover Study To Estimate The Interaction Between Multiple Dose Rifabutin And Lersivirine (UK-453,061) In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2012

At a glance

  • Drugs Lersivirine (Primary) ; Rifabutin (Primary)
  • Indications HIV infections; Mycobacterium avium complex infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 May 2012 Results published in Antimicrobial Agents and Chemotherapy.
    • 07 Sep 2010 Actual end date added to 1 Aug 2010 as reported by ClinicalTrials.gov.
    • 07 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top